215 related articles for article (PubMed ID: 36983271)
1. Proton Pump Inhibitors and Risk of Chronic Kidney Disease: Evidence from Observational Studies.
Wu CC; Liao MH; Kung WM; Wang YC
J Clin Med; 2023 Mar; 12(6):. PubMed ID: 36983271
[TBL] [Abstract][Full Text] [Related]
2. Investigating the association of proton pump inhibitors with chronic kidney disease and its impact on clinical practice and future research: a review.
Cheema E
J Pharm Policy Pract; 2019; 12():6. PubMed ID: 30976431
[TBL] [Abstract][Full Text] [Related]
3. Proton pump inhibitors and risk of hip fracture: a meta-analysis of observational studies.
Poly TN; Islam MM; Yang HC; Wu CC; Li YJ
Osteoporos Int; 2019 Jan; 30(1):103-114. PubMed ID: 30539272
[TBL] [Abstract][Full Text] [Related]
4. The association between proton pump inhibitor use and the risk of adverse kidney outcomes: a systematic review and meta-analysis.
Nochaiwong S; Ruengorn C; Awiphan R; Koyratkoson K; Chaisai C; Noppakun K; Chongruksut W; Thavorn K
Nephrol Dial Transplant; 2018 Feb; 33(2):331-342. PubMed ID: 28339835
[TBL] [Abstract][Full Text] [Related]
5. Associations of Proton-Pump Inhibitors and H2 Receptor Antagonists with Chronic Kidney Disease: A Meta-Analysis.
Wijarnpreecha K; Thongprayoon C; Chesdachai S; Panjawatanana P; Ungprasert P; Cheungpasitporn W
Dig Dis Sci; 2017 Oct; 62(10):2821-2827. PubMed ID: 28836158
[TBL] [Abstract][Full Text] [Related]
6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
7. Proton Pump Inhibitor Use and Risk of Gastric Cancer: Current Evidence from Epidemiological Studies and Critical Appraisal.
Poly TN; Lin MC; Syed-Abdul S; Huang CW; Yang HC; Li YJ
Cancers (Basel); 2022 Jun; 14(13):. PubMed ID: 35804824
[TBL] [Abstract][Full Text] [Related]
8. The treatment efficacy of adding prokinetics to PPIs for gastroesophageal reflux disease: a meta-analysis.
Xi L; Zhu J; Zhang H; Muktiali M; Li Y; Wu A
Esophagus; 2021 Jan; 18(1):144-151. PubMed ID: 32519226
[TBL] [Abstract][Full Text] [Related]
9. A Meta-Analysis of Proton Pump Inhibitor Use and the Risk of Acute Kidney Injury: Geographical Differences and Associated Factors.
Han CT; Islam MM; Poly TN; Lu YC; Lin MC
J Clin Med; 2023 Mar; 12(7):. PubMed ID: 37048551
[TBL] [Abstract][Full Text] [Related]
10. Proton Pump Inhibitors and Risk of Acute and Chronic Kidney Disease: A Retrospective Cohort Study.
Hart E; Dunn TE; Feuerstein S; Jacobs DM
Pharmacotherapy; 2019 Apr; 39(4):443-453. PubMed ID: 30779194
[TBL] [Abstract][Full Text] [Related]
11. The Safety of Long-Term Proton Pump Inhibitor Use on Cardiovascular Health: A Meta-Analysis.
Jeridi D; Pellat A; Ginestet C; Assaf A; Hallit R; Corre F; Coriat R
J Clin Med; 2022 Jul; 11(14):. PubMed ID: 35887860
[TBL] [Abstract][Full Text] [Related]
12. Meta-analyses: does long-term PPI use increase the risk of gastric premalignant lesions?
Eslami L; Nasseri-Moghaddam S
Arch Iran Med; 2013 Aug; 16(8):449-58. PubMed ID: 23906249
[TBL] [Abstract][Full Text] [Related]
13. Proton pump inhibitors use and risk of chronic kidney disease and end-stage renal disease.
Vengrus CS; Delfino VD; Bignardi PR
Minerva Urol Nephrol; 2021 Aug; 73(4):462-470. PubMed ID: 33769018
[TBL] [Abstract][Full Text] [Related]
14. Proton pump inhibitors and adverse effects in kidney transplant recipients: A meta-analysis.
Boonpheng B; Thongprayoon C; Bathini T; Sharma K; Mao MA; Cheungpasitporn W
World J Transplant; 2019 Jun; 9(2):35-47. PubMed ID: 31363460
[TBL] [Abstract][Full Text] [Related]
15. Association and Mechanisms of Proton Pump Inhibitors Use with Type-2 Diabetes Mellitus Incidence in Adults: A Systemic Review and Metaanalysis.
Chenchula S; Sharma P; Ghanta MK; Amerneni KC; Rajakarunakaran P; Saggurthi P; Chandra MB; Gupta R; Chavan M
Curr Diabetes Rev; 2024 Jan; ():. PubMed ID: 38243950
[TBL] [Abstract][Full Text] [Related]
16. Proton pump inhibitors for functional dyspepsia.
Pinto-Sanchez MI; Yuan Y; Hassan A; Bercik P; Moayyedi P
Cochrane Database Syst Rev; 2017 Nov; 11(11):CD011194. PubMed ID: 29161458
[TBL] [Abstract][Full Text] [Related]
17. Proton-pump inhibitors use, and risk of acute kidney injury: a meta-analysis of observational studies.
Yang Y; George KC; Shang WF; Zeng R; Ge SW; Xu G
Drug Des Devel Ther; 2017; 11():1291-1299. PubMed ID: 28479851
[TBL] [Abstract][Full Text] [Related]
18. Proton pump inhibitors for chronic obstructive pulmonary disease.
Kikuchi S; Imai H; Tani Y; Tajiri T; Watanabe N
Cochrane Database Syst Rev; 2020 Aug; 8(8):CD013113. PubMed ID: 32844430
[TBL] [Abstract][Full Text] [Related]
19. Effect of proton pump inhibitors on the risk of chronic kidney disease: A propensity score-based overlap weight analysis using the United Kingdom Biobank.
Zhang XY; He QS; Jing Z; He JX; Yuan JQ; Dai XY
Front Pharmacol; 2022; 13():949699. PubMed ID: 36438798
[No Abstract] [Full Text] [Related]
20. Proton pump inhibitors are associated with increased risk of development of chronic kidney disease.
Arora P; Gupta A; Golzy M; Patel N; Carter RL; Jalal K; Lohr JW
BMC Nephrol; 2016 Aug; 17(1):112. PubMed ID: 27487959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
